This action might not be possible to undo. Are you sure you want to continue?
From discovery to development and commercialisation, they have the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market. Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. It mainly focuses on unmet medical needs in cancer, diabetes and inflammatory diseases and offers novel therapies on a platform of affordable innovation. Over the years, BIOCON have systematically leveraged our technology platforms from enzymes to small molecules to recombinant proteins and antibodies. Through partnerships and alliances, Biocon has strategically moved up the value chain from supplying pharmaceutical bulk actives to developing proprietary molecules and their own branded formulations.
Biocon is a fully integrated biotechnology enterprise focused on the development of biopharmaceuticals. With its outstanding scientific knowledge pool, proprietary technologies and worldclass facilities, it is delivering "value differential" solutions to its partners and customers in more than 50 countries. Biocon is committed to find biotechnology solutions for the patients of diabetes and cancer. On March 8th 2007, Biocon launched its Nephrology Division and a comprehensive range of renal therapy products. This Nephrology Division will find solution to kidney disorders through progressive research and new therapies. While doing this, it will use the highest standards of biotherapeutics.
consisting of chemists. In 2004 it introduced new generation bio-insulin-INSUGEN. In 1998. computer . Clinigene. And in the year 2003. Biocon together with Syngene and Clinigene has employee strength of about 2000. was set up to pursue clinical researches and developments. which is a subsidiary of Biocon. mentoring and empowerment • The company was founded on 29th November 1978. It has emerged from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise. In the year 2000. Biocon became the first company to develop human insulin on a Pichia expression system.The company is achieving excellence through: Intellectual asset creation • State-of-art manufacturing capabilities • International benchmarks for the quality and regulatory systems • Disease-specific clinical research • Development of Human Resource through training. Biocon launched India's first cancer drug. In 2006. which is focused on healthcare. the company's proprietary fermentation plant had commercial success that led to 3-fold expansion. the company became an independent entity when Unilever agreed to sell its shareholding in Biocon to the promoter. In 1979 it became the first company to manufacture and export enzymes to USA and Europe. It possesses a rare combination of proprietary fermentation technology and research skills. In 1996.BIOMAb EGFR.
scientists. chemists. . engineers. market analysts and biologists. medical practitioners.